<!DOCTYPE html>
<!--[if (gt IE 9)|!(IE)]> <!--> <html lang="en" class="no-js has-comments blog-news section-"  itemscope xmlns:og="//opengraphprotocol.org/schema/"> <!--<![endif]-->
<!--[if IE 9]> <html lang="en" class="no-js ie9 lt-ie10 has-comments blog-news section-" xmlns:og="//opengraphprotocol.org/schema/"> <![endif]-->
<!--[if IE 8]> <html lang="en" class="no-js ie8 lt-ie10 lt-ie9 has-comments blog-news section-" xmlns:og="//opengraphprotocol.org/schema/"> <![endif]-->
<!--[if (lt IE 8)]> <html lang="en" class="no-js lt-ie10 lt-ie9 lt-ie8 has-comments blog-news section-" xmlns:og="//opengraphprotocol.org/schema/"> <![endif]-->
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o||n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({1:[function(e,n,t){function r(){}function o(e,n,t){return function(){return i(e,[c.now()].concat(u(arguments)),n?null:this,t),n?void 0:this}}var i=e("handle"),a=e(2),u=e(3),f=e("ee").get("tracer"),c=e("loader"),s=NREUM;"undefined"==typeof window.newrelic&&(newrelic=s);var p=["setPageViewName","setCustomAttribute","setErrorHandler","finished","addToTrace","inlineHit","addRelease"],d="api-",l=d+"ixn-";a(p,function(e,n){s[n]=o(d+n,!0,"api")}),s.addPageAction=o(d+"addPageAction",!0),s.setCurrentRouteName=o(d+"routeName",!0),n.exports=newrelic,s.interaction=function(){return(new r).get()};var m=r.prototype={createTracer:function(e,n){var t={},r=this,o="function"==typeof n;return i(l+"tracer",[c.now(),e,t],r),function(){if(f.emit((o?"":"no-")+"fn-start",[c.now(),r,o],t),o)try{return n.apply(this,arguments)}finally{f.emit("fn-end",[c.now()],t)}}}};a("setName,setAttribute,save,ignore,onEnd,getContext,end,get".split(","),function(e,n){m[n]=o(l+n)}),newrelic.noticeError=function(e){"string"==typeof e&&(e=new Error(e)),i("err",[e,c.now()])}},{}],2:[function(e,n,t){function r(e,n){var t=[],r="",i=0;for(r in e)o.call(e,r)&&(t[i]=n(r,e[r]),i+=1);return t}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],3:[function(e,n,t){function r(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(o<0?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=r},{}],4:[function(e,n,t){n.exports={exists:"undefined"!=typeof window.performance&&window.performance.timing&&"undefined"!=typeof window.performance.timing.navigationStart}},{}],ee:[function(e,n,t){function r(){}function o(e){function n(e){return e&&e instanceof r?e:e?f(e,u,i):i()}function t(t,r,o,i){if(!d.aborted||i){e&&e(t,r,o);for(var a=n(o),u=m(t),f=u.length,c=0;c<f;c++)u[c].apply(a,r);var p=s[y[t]];return p&&p.push([b,t,r,a]),a}}function l(e,n){v[e]=m(e).concat(n)}function m(e){return v[e]||[]}function w(e){return p[e]=p[e]||o(t)}function g(e,n){c(e,function(e,t){n=n||"feature",y[t]=n,n in s||(s[n]=[])})}var v={},y={},b={on:l,emit:t,get:w,listeners:m,context:n,buffer:g,abort:a,aborted:!1};return b}function i(){return new r}function a(){(s.api||s.feature)&&(d.aborted=!0,s=d.backlog={})}var u="nr@context",f=e("gos"),c=e(2),s={},p={},d=n.exports=o();d.backlog=s},{}],gos:[function(e,n,t){function r(e,n,t){if(o.call(e,n))return e[n];var r=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:r,writable:!0,enumerable:!1}),r}catch(i){}return e[n]=r,r}var o=Object.prototype.hasOwnProperty;n.exports=r},{}],handle:[function(e,n,t){function r(e,n,t,r){o.buffer([e],r),o.emit(e,n,t)}var o=e("ee").get("handle");n.exports=r,r.ee=o},{}],id:[function(e,n,t){function r(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:a(e,i,function(){return o++})}var o=1,i="nr@id",a=e("gos");n.exports=r},{}],loader:[function(e,n,t){function r(){if(!x++){var e=h.info=NREUM.info,n=d.getElementsByTagName("script")[0];if(setTimeout(s.abort,3e4),!(e&&e.licenseKey&&e.applicationID&&n))return s.abort();c(y,function(n,t){e[n]||(e[n]=t)}),f("mark",["onload",a()+h.offset],null,"api");var t=d.createElement("script");t.src="https://"+e.agent,n.parentNode.insertBefore(t,n)}}function o(){"complete"===d.readyState&&i()}function i(){f("mark",["domContent",a()+h.offset],null,"api")}function a(){return E.exists&&performance.now?Math.round(performance.now()):(u=Math.max((new Date).getTime(),u))-h.offset}var u=(new Date).getTime(),f=e("handle"),c=e(2),s=e("ee"),p=window,d=p.document,l="addEventListener",m="attachEvent",w=p.XMLHttpRequest,g=w&&w.prototype;NREUM.o={ST:setTimeout,SI:p.setImmediate,CT:clearTimeout,XHR:w,REQ:p.Request,EV:p.Event,PR:p.Promise,MO:p.MutationObserver};var v=""+location,y={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-1044.min.js"},b=w&&g&&g[l]&&!/CriOS/.test(navigator.userAgent),h=n.exports={offset:u,now:a,origin:v,features:{},xhrWrappable:b};e(1),d[l]?(d[l]("DOMContentLoaded",i,!1),p[l]("load",r,!1)):(d[m]("onreadystatechange",o),p[m]("onload",r)),f("mark",["firstbyte",u],null,"api");var x=0,E=e(4)},{}]},{},["loader"]);</script>
		<meta name="PT" content="Blogs" />
<meta name="PST" content="Blog Post" />
<meta name="sourceApp" content="blogs" />
<meta itemprop="identifier" name="blogpostid" content="100000003821823"><meta name="author" content="Amie Tsang" />
<meta name="CLMST" content="Amie Tsang" />
<meta name="byl" content="Amie Tsang" />
<meta name="GBLC" content="DealBook">
<meta name="PUV" content="normal" />
<meta property="article:published_time" itemprop="datePublished" content="1437995329" />
<meta name="PUD" content="20150727" />
<meta name="pdate" content="20150727" />
<meta name="ptime" content="20150727070849" />
<meta name="utime" content="20150727110849" />
<meta property="article:modified_time" itemprop="dateModified" content="2015-07-27T11:08:49-04:00" />
<meta name="DISPLAYDATE" content="July 27, 2015" />
<meta name="dat" content="July 27, 2015" />
<meta itemprop="articleSection" property="article:section" content="" />
<meta name="CG" content="" />
<meta name="SCG" content="news" />
<meta name="BN" content="news" />
<meta name="robots" content="noodp">
<meta name="per" content="Ackman, William A">
<meta name="des" content="Bitcoin (Currency);Bloomberg LP;Botox (Drug);Carlyle Group LP;China;Futures and Options Trading;Mergers, Acquisitions and Divestitures;National Debt (US);News and News Media;Pearson PLC;Private Equity;Puerto Rico;Stocks and Bonds;Venture Capital">
<meta name="org" content="Actavis PLC;Allergan Inc;Deutsche Bank AG;Drugs (Pharmaceuticals);Exor SpA;Fidelity Investments;Teva Pharmaceutical Industries Ltd;UBS A.G.;Valeant Pharmaceuticals International Inc">
<meta name="ticker" content="Actavis PLC|ACT|NYSE;Allergan Inc|AGN|NYSE;Deutsche Bank AG|DB|NYSE;UBS A.G.|OUBS|NYSE;Valeant Pharmaceuticals International Inc|VRX|NYSE" />
<meta property="article:tag" content="Ackman William A" />
<meta property="article:tag" content="Bitcoin (Currency)" />
<meta property="article:tag" content="Bloomberg LP" />
<meta property="article:tag" content="Botox (Drug)" />
<meta property="article:tag" content="Carlyle Group LP" />
<meta property="article:tag" content="China" />
<meta property="article:tag" content="Futures and Options Trading" />
<meta property="article:tag" content="Mergers Acquisitions and Divestitures" />
<meta property="article:tag" content="National Debt (US)" />
<meta property="article:tag" content="News and News Media" />
<meta property="article:tag" content="Pearson PLC" />
<meta property="article:tag" content="Private Equity" />
<meta property="article:tag" content="Puerto Rico" />
<meta property="article:tag" content="Stocks and Bonds" />
<meta property="article:tag" content="Venture Capital" />
<meta property="article:tag" content="Actavis PLC" />
<meta property="article:tag" content="Allergan Inc" />
<meta property="article:tag" content="Deutsche Bank AG" />
<meta property="article:tag" content="Drugs (Pharmaceuticals)" />
<meta property="article:tag" content="Exor SpA" />
<meta property="article:tag" content="Fidelity Investments" />
<meta property="article:tag" content="Teva Pharmaceutical Industries Ltd" />
<meta property="article:tag" content="UBS A.G." />
<meta property="article:tag" content="Valeant Pharmaceuticals International Inc" />
<meta property="article:tag" content="DealBook" />
<meta name="keywords" content="Ackman William A,Bitcoin (Currency),Bloomberg LP,Botox (Drug),Carlyle Group LP,China,Futures and Options Trading,Mergers Acquisitions and Divestitures,National Debt (US),News and News Media,Pearson PLC,Private Equity,Puerto Rico,Stocks and Bonds,Venture Capital,Actavis PLC,Allergan Inc,Deutsche Bank AG,Drugs (Pharmaceuticals),Exor SpA,Fidelity Investments,Teva Pharmaceutical Industries Ltd,UBS A.G.,Valeant Pharmaceuticals International Inc,DealBook" />
<link rel="alternate" type="application/json+oembed" href="https://www.nytimes.com/svc/oembed/json/?url=http%3A%2F%2Fnews.blogs.nytimes.com%2F2015%2F07%2F27%2Fmorning-agenda-teva-to-buy-allergan-generic-drug-unit%2F" title="Morning Agenda: Teva to Buy Allergan Generic Drug Unit" />
<meta name="description" content="Fidelity Seen as Muscling In &#124; Pearson Discusses Selling Economist Stake &#124; Bitcoin is the New Ransom Currency &#124; China Stock Sell-Off" />
<meta name="hdl" content="Morning Agenda: Teva to Buy Allergan Generic Drug Unit" />
<meta property="og:title" content="Morning Agenda: Teva to Buy Allergan Generic Drug Unit" />
<meta property="og:type" content="article" />
<meta property="og:url" content="//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/" />
<meta property="og:site_name" content="" />
<meta property="og:description" content="Fidelity Seen as Muscling In &#124; Pearson Discusses Selling Economist Stake &#124; Bitcoin is the New Ransom Currency &#124; China Stock Sell-Off" />
<meta property="og:image" content="https://static01.nyt.com/images/blogs_v5/../icons/t_logo_2048_black.png"/>
<meta name="thumbnail_150" content="https://static01.nyt.com/packages/images/icons/t_logo_300_black.png"/>
<meta name="twitter:card" value="summary"><meta name="twitter:title" content="Morning Agenda: Teva to Buy Allergan Generic Drug Unit" />
<meta name="twitter:url" content="//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/" />
<meta name="twitter:description" content="Fidelity Seen as Muscling In &#124; Pearson Discusses Selling Economist Stake &#124; Bitcoin is the New Ransom Currency &#124; China Stock Sell-Off" />
<meta name="twitter:image" content="https://static01.nyt.com/packages/images/icons/t_logo_300_black.png"/>
<meta itemprop="thumbnailUrl" content="https://static01.nyt.com/packages/images/icons/t_logo_300_black.png" name="thumbnail" />
<link rel='prev' title='What We&#8217;re Reading' href='//news.blogs.nytimes.com/2015/07/24/what-were-reading-75/' />
<link rel='next' title='Morning Agenda: Executive Strategy at Bank of America' href='//news.blogs.nytimes.com/2015/07/28/morning-agenda-executive-strategy-at-bank-of-america/' />
<link rel='canonical' href='//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/' />
<link rel='shortlink' href='//nyti.ms/1GTTPzc' />
<link rel='https://github.com/WP-API/WP-API' href='//news.blogs.nytimes.com/json' />
<meta name="adxPage" content="blog.nytimes.com/news/post" />
<link rel="alternate" type="application/rss+xml" title="RSS 2.0" href="//news.blogs.nytimes.com/feed/" />
<meta property="article:collection" content="https://static01.nyt.com/services/json/sectionfronts/index.jsonp" />
<link rel="alternate" href="//mobile.nytimes.com/blogs/news/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/" />
<meta name="dfp-ad-unit-path" content="news" />			<title>Morning Agenda: Teva to Buy Allergan Generic Drug Unit - The New York Times</title>
            <!--[if (gt IE 9)|!(IE)]> <!-->
    <link rel="stylesheet" type="text/css" media="screen" href="https://int.nyt.com/assets/blogs/latest/css/blogs/styles.css" />
<!--<![endif]-->
<!--[if lte IE 9]>
    <link rel="stylesheet" type="text/css" media="screen" href="https://int.nyt.com/assets/blogs/latest/css/blogs/styles-ie.css" />
<![endif]-->
<link rel="stylesheet" type="text/css" media="screen" href="https://int.nyt.com/assets/blogs/latest/css/blogs/news.css" />
<link rel="stylesheet" type="text/css" media="print" href="https://int.nyt.com/assets/blogs/latest/css/blogs/styles-print.css" />
<script>
var NYT = NYT || {}, NYTD = NYTD || {};
</script>
                        	<script src="https://int.nyt.com/assets/blogs/latest/js/blogs/layout.js"></script>
	<script type="text/javascript">var googletag=googletag||{};googletag.cmd=googletag.cmd||[],function(){var t=document.createElement("script");t.async=!0,t.type="text/javascript";var e="https:"==document.location.protocol;t.src=(e?"https:":"http:")+"//www.googletagservices.com/tag/js/gpt.js";var o=document.getElementsByTagName("script")[0];if (!/NYT-T=out/.test(document.cookie)) {o.parentNode.insertBefore(t,o)}}();</script>
<script id="magnum-feature-flags" type="application/json">["limitFabrikSave","facebookOauthButton","videoVHSCover","videoVHSShareTools","videoVHSEmbeddedOnly","removeInternationalEdition","piiBlockDFP","indexAsHeaderBidder","caslOpt"]</script>
<script>
var require = {
    baseUrl: 'https://int.nyt.com/assets/',
    waitSeconds: 20,
    paths: {
        'foundation': 'blogs/latest/js/foundation',
        'shared': 'blogs/latest/js/shared',
        'blogs': 'blogs/latest/js/blogs',
        'auth/mtr': 'https://static01.nyt.com/js/mtr',
        'auth/growl': 'https://static01.nyt.com/js/auth/growl/default',
        'vhs': 'https://static01.nyt.com/video/vhs/build/vhs-2.x.min'
    }
};
</script>
<!--[if (gte IE 9)|!(IE)]> <!-->
<script data-main="foundation/main" src="https://int.nyt.com/assets/blogs/latest/js/foundation/lib/framework.js"></script>
<!--<![endif]-->
<!--[if lt IE 9]>
<script>
require.map = { '*': { 'foundation/main': 'foundation/legacy_main' } };
</script>
<script data-main="foundation/legacy_main" src="https://int.nyt.com/assets/blogs/latest/js/foundation/lib/framework.js"></script>
<![endif]-->
<script>
require(['foundation/main'], function () {
    require(['auth/mtr']);
});
</script>
<!--esi
<script id="user-info-data" type="application/json">
<esi:include src="/svc/web-products/userinfo-v3.json" />
</script>
-->
    	</head><body class="single single-post postid-2866 blog-universal nyt-blog-news full-width-headline" id="" data-env="production" data-region="ewr1">
	<div id="shell" class="shell">
			<header id="masthead" class="masthead masthead-theme-standard" role="banner">
    <div class="container">
        <div class="quick-navigation button-group">
            <button class="button sections-button"><i class="icon sprite-icon"></i><span class="button-text">Sections</span></button>
            <button class="button home-button" data-href="https://www.nytimes.com/" title="Go to the home page to see the latest top stories."><i class="icon sprite-icon"></i>
                <span class="button-text">Home</span>
            </button>
            <button class="button search-button"><i class="icon sprite-icon"></i><span class="button-text">Search</span></button>
            <a class="button skip-button skip-to-content visually-hidden focusable" href="#main">Skip to content</a>
                                </div><!-- close button-group -->
        <div class="branding">
            <h2 class="branding-heading">
                <a id="branding-heading-link" href="https://www.nytimes.com/">
                    <span class="visually-hidden">The New York Times</span>
                </a>
            </h2>
            <script>window.magnum.writeLogo('small', 'https://int.nyt.com/assets/blogs/latest/images/foundation/logos/', '', 'masthead-theme-standard', 'standard', 'branding-heading-link', 'blogs');</script>
        </div><!-- close branding -->
        <div class="story-meta">
    <h6 class="kicker">
        <span class="kicker-label">
			            <a href="//news.blogs.nytimes.com">
                News            </a>
			        </span>

                <span class="pipe">|</span>
        Morning Agenda: Teva to Buy Allergan Generic Drug Unit        
    </h6>
</div><!-- close story-meta -->


        <div class="user-tools">
            <div id="Bar1" class="ad bar1-ad nocontent robots-nocontent"></div>
            <div id="sharetools-masthead" class="sharetools theme-classic"
	 data-shares="email,facebook,twitter,show-all|More"
	 data-url="//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/"
	 data-title="Morning Agenda: Teva to Buy Allergan Generic Drug Unit"
	 data-description="&lt;span class=&quot;excerpt-inner&quot;&gt;Fidelity Seen as Muscling In | Pearson Discusses Selling Economist Stake | Bitcoin is the New Ransom Currency | China Stock Sell-Off&lt;/span&gt;&lt;a href=&quot;//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/&quot; class=&quot;more-link&quot;&gt;Read&nbsp;more...&lt;/a&gt;"
	data-publish-date="July 27, 2015 7:08 am">
<div class="ad sharetools-inline-article-ad hidden"></div>
</div><!-- close shareTools -->
            <button class="button search-button"><i class="icon sprite-icon"></i><span class="button-text">Search</span></button>
            <div class="user-tools-button-group button-group">
                <button class="button subscribe-button hidden" data-href="https://www.nytimes.com/subscriptions/Multiproduct/lp3004.html?campaignId=4XUYF">Subscribe Now</button>
                <button class="button login-button login-modal-trigger hidden">Log In</button>
                <button class="button comments-button  button-masthead" data-skip-to-para-id="">
</button>
                                <button class="button notifications-button hidden"><i class="icon sprite-icon"></i><span class="button-text">0</span></button>
                <button class="button user-settings-button"><i class="icon sprite-icon"></i><span class="button-text">Settings</span></button>
            </div><!-- close user-tools-button-group -->
        </div><!-- close user-tools -->
    </div><!-- close container -->
    <div class="search-flyout-panel flyout-panel">
    <button class="button close-button" type="button"><i class="icon"></i><span class="visually-hidden">Close search</span></button>
    <nav class="search-form-control form-control layout-horizontal">
    <h2 class="visually-hidden">Site Search Navigation</h2>
    <form class="search-form" role="search">
        <div class="control">
            <div class="label-container visually-hidden">
                                <label for="search-input">Search NYTimes.com</label>
                            </div>
            <div class="field-container">
                                <input id="search-input" name="search-input" type="text" class="search-input text" autocomplete="off" placeholder="Search NYTimes.com" />
                
                <button type="button" class="button clear-button" tabindex="-1" aria-describedby="clear-search-input"><i class="icon"></i><span id="clear-search-input" class="visually-hidden">Clear this text input</span></button>
                <div class="auto-suggest" style="display: none;">
                    <ol></ol>
                </div>
                <button class="button submit-button" type="submit">Go</button>
            </div>
        </div><!-- close control -->
    </form>
</nav>


</div><!-- close flyout-panel -->
    <div id="notification-modals" class="notification-modals"></div>
</header>
					<nav id="ribbon" class="ribbon ribbon-start nocontent robots-nocontent" aria-hidden="true">
    <div class="nocontent robots-nocontent">
        <ol class="ribbon-menu">
            <li class="collection ribbon-loader">
                <div class="loader "><span class="visually-hidden">Loading...</span></div>
            </li>
        </ol>
        <div class="ribbon-navigation-container">
            <nav class="ribbon-navigation next">
                <span class="visually-hidden">See next articles</span>
                <div class="arrow arrow-right">
                    <div class="arrow-conceal"></div>
                </div>
            </nav>
            <nav class="ribbon-navigation previous">
                <span class="visually-hidden">See previous articles</span>
                <div class="arrow arrow-left">
                    <div class="arrow-conceal"></div>
                </div>
            </nav>
        </div>
    </div><!-- close nocontent -->
</nav>
						<nav id="navigation" class="navigation">
    <h2 class="visually-hidden">Site Navigation</h2>
</nav><!-- close navigation -->

<nav id="mobile-navigation" class="mobile-navigation hidden">
    <h2 class="visually-hidden">Site Mobile Navigation</h2>
</nav><!-- close mobile-navigation -->

    <div id="navigation-edge" class="navigation-edge"></div>
				<main id="main" class="main" role="main">
				<div id="TopAd" class="ad top-ad"></div>
				<div id="mobilebanner" class="ad mobilebanner"></div>
								<div id="story" class="story theme-main">
		<div id="news" class="spanAC blog">
				<div class="postHeader story-header">
	<div class="story-meta">
						<h1 class="entry-title story-heading">Morning Agenda: Teva to Buy Allergan Generic Drug Unit</h1>
		<div class="story-meta-footer">
			<address class="byline author vcard" itemprop="author creator" itemtype="//schema.org/Person">
				By Amie Tsang			</address>
			<!-- date published --><time class="dateline " datetime="2015-07-27T11:08:49+00:00" itemprop="datePublished">July 27, 2015</time>
			<!-- date updated --><span class="visually-hidden updated">July 27, 2015</span>			<div class="inside-story"></div><!-- Although this is empty, it is required for layout parity with NYT5 -->
		</div>
	</div>
</div>
<div class="a-column" id="a-col">
	<div id="content" class="hfeed">
			<article class="post-2866 post type-post status-publish hentry category-dealbook tag-ackman-william-a tag-actavis-plc tag-allergan-inc tag-bitcoin-currency tag-bloomberg-lp tag-botox-drug tag-carlyle-group-lp tag-china tag-deutsche-bank-ag tag-drugs-pharmaceuticals tag-exor-spa tag-fidelity-investments tag-futures-and-options-trading tag-mergers-acquisitions-and-divestitures tag-national-debt-us tag-news-and-news-media tag-pearson-plc tag-private-equity tag-puerto-rico tag-stocks-and-bonds tag-teva-pharmaceutical-industries-ltd tag-ubs-a-g tag-valeant-pharmaceuticals-international-inc tag-venture-capital per-ackman-william-a des-bitcoin-currency des-bloomberg-lp des-botox-drug des-carlyle-group-lp des-china des-futures-and-options-trading des-mergers-acquisitions-and-divestitures des-national-debt-us des-news-and-news-media des-pearson-plc des-private-equity des-puerto-rico des-stocks-and-bonds des-venture-capital org-actavis-plc org-allergan-inc org-deutsche-bank-ag org-drugs-pharmaceuticals org-exor-spa org-fidelity-investments org-teva-pharmaceutical-industries-ltd org-ubs-a-g org-valeant-pharmaceuticals-international-inc" id="post-2866">
                        <div class="visually-hidden">
                <span itemprop="headline" class="entry-title">Morning Agenda: Teva to Buy Allergan Generic Drug Unit</span>
                <span class="byline author vcard" itemprop="author creator" itemtype="//schema.org/Person">
                    By Amie Tsang                </span>
                <!-- date published --><time class="dateline " datetime="2015-07-27T11:08:49+00:00" itemprop="datePublished">July 27, 2015 7:08 am</time>
			<!-- date updated --><span class="visually-hidden updated">July 27, 2015 7:08 am</span>            </div>
			<div class="entry-content">
			<div id="sharetools-story" class="sharetools theme-classic sharetools-story" data-shares="email|Email,facebook|Share,twitter|Tweet,save|Save,show-all|More,ad" data-url="//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/" data-title="Morning Agenda: Teva to Buy Allergan Generic Drug Unit" data-description="Fidelity Seen as Muscling In | Pearson Discusses Selling Economist Stake | Bitcoin is the New Ransom Currency | China Stock Sell-Off">
				<div class="ad sharetools-inline-article-ad"></div>
				<div id="MiddleLeft" class="ad middle-left-ad nocontent robots-nocontent"></div>
				</div><div class="round-up">
<div class="ru-top-story">
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>TEVA TO BUY ALLERGAN GENERIC DRUG UNIT</strong> <span class="divider"> | </span></span> The Israeli drug maker Teva has agreed to buy Allerganâs <b>generic drug division for $40.5 billion in cash and stock</b>, <a href="//www.nytimes.com/2015/07/28/business/dealbook/teva-pharmaceuticals-to-buy-allergans-generics-business.html?partner=socialflow&#038;smid=tw-nytimesbusiness">Chad Bray reports in DealBook</a>. The transaction would create a company with estimated, pro forma revenue of $26 billion in 2016, including about $11 billion in sales outside the United States, Teva said. Under the terms of the deal, Allergan would receive $33.75 billion in cash and shares worth about $6.75 billion, representing an ownership stake of under 10 percent in Teva.</p>
<p class="story-body-text" itemprop="articleBody"> The deal could bolster Tevaâs market position as the worldâs biggest seller of generic medicines, <a href="//www.nytimes.com/2015/07/27/business/teva-said-to-be-close-to-buying-generic-drug-unit-of-allergan.html?rref=business/dealbook&#038;module=ArrowsNav&#038;contentCollection=DealBook&#038;action=keypress&#038;region=FixedRight&#038;pgtype=article">Michael J. de la Merced notes in DealBook</a>. The acquisition may also end Tevaâs monthslong pursuit of Mylan, a rival that has rebuffed takeover offers and is trying to buy another drug maker. <a href="//www.wsj.com/articles/teva-in-advanced-talks-to-buy-allergans-generic-drug-unit-1437861351">The Wall Street Journal</a>, which had reported the deal, notes that Teva is under pressure because its top selling product, a brand-name multiple sclerosis treatment called Copaxone, is facing <b>lower-priced competition</b> in the United States. </p>
<p class="story-body-text" itemprop="articleBody"> Allergan is a powerhouse with a market value of more than $120 billion, made up of Actavis, a generic drug maker; and Allergan, best known as the maker of Botox. The old Allergan entity had been fending off <b>an unwanted takeover bid</b> by Valeant Pharmaceuticals and the hedge fund magnate William A. Ackman. Actavis trumped Valeantâs $53 billion offer by paying $66 billion and then took Allerganâs name. </p>
<p class="story-body-text" itemprop="articleBody"> The Actavis-Allergan deal was <b>aimed at diversifying</b> beyond generic drugs, a business that is increasingly saturated with products with lower profit margins. Allergan is now looking at parting ways with this major business line and announced on Sunday that it had agreed to buy a developer of drugs for depression and other central nervous system disorders.</p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>FIDELITY SEEN AS MUSCLING IN</strong> <span class="divider"> | </span></span> The steward of Fidelity Management and Research, a $5.2 trillion mutual fund and asset management empire, promises to treat investors fairly and put their interests first, but shareholders in the small British telecom company Colt say Fidelity is taking a decidedly different approach, <a href="//www.nytimes.com/2015/07/26/business/fidelity-seen-as-muscling-investors-out-of-upside-in-a-telecom-deal.html?ref=business">Gretchen Morgenson writes in the Fair Game column</a>. They say the mutual fund is putting its own interests ahead of other Colt owners by forcing them to accept its buyout offer for the company at a <b>bargain-basement price</b>. </p>
<p class="story-body-text" itemprop="articleBody"> After being a star in the early 2000s, Coltâs stock collapsed when the tech stock bubble burst and has rarely traded above 200 pence, or about $3, in the last decade. But its <b>fortunes may be changing</b>, shareholders say. They object to Fidelityâs 190-pence bid for the shares it doesnât already own, saying that recent acquisitions of operations similar to Coltâs were completed at much higher prices. </p>
<p class="story-body-text" itemprop="articleBody"> Although dissenting shareholders agree that an <b>auction of the company</b>, where interested companies could make their best offers, is the right thing to do, Fidelity has made this impossible. Its bid notes that it would not sell its shares to any third party before December 2016. </p>
<p class="story-body-text" itemprop="articleBody"> âIn this situation where Colt is an illiquid stock, itâs <b>difficult for a white knight</b> to show up and protect the minorities,â says Andrew Sinwell, a longtime telecom investor and chief executive of an investment firm that owns Colt shares.</p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>PEARSON DISCUSSES SELLING ECONOMIST STAKE</strong> <span class="divider"> | </span></span> The British education company Pearson said it was in talks to sell its 50 percent stake in the Economist Group, <a href="//www.nytimes.com/2015/07/26/business/media/pearson-in-talks-to-sell-its-stake-of-the-economist-group.html?ref=dealbook">Ravi Somaiya reports in DealBook</a>. Pearson just last week reached a deal to sell The Financial Times to the Japanese media group Nikkei for $1.3 billion, saying it wanted to focus on its core education business. Pearsonâs stake in the Economist Group is reported to be <b>worth more than $600 million</b>. </p>
<p class="story-body-text" itemprop="articleBody"> The talks about The Economist are focused on <b>other shareholders of the group</b>, including wealthy families like the Schroders, the Cadburys and the Agnellis, <a href="//www.ft.com/cms/s/0/584d6462-33a1-11e5-b05b-b01debd57852.html?ftcamp=published_links%2Frss%2Fcompanies%2Ffeed%2F%2Fproduct#axzz3h43hFV1A">The Financial Times reports</a>. Exor, the Agnelli familyâs holding company, is reported to be in talks to raise its 4.72 percent stake in the Economist Group. </p>
<p class="story-body-text" itemprop="articleBody"> The German media company Axel Springer and the financial information company Bloomberg have also been approached after they came close to buying The Financial Times, but both <b>declined to pursue</b> the purchase because owning shares would not allow control.</p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>ON THE AGENDA</strong> <span class="divider"> | </span></span> <b>Durable goods orders</b> for June will be reported at 8:30 a.m. <b>Baidu</b> will hold an earnings conference call at 8 p.m.</p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>BITCOIN IS THE NEW RANSOM CURRENCY</strong> <span class="divider"> | </span></span> Forget the briefcase of unmarked bills. Modern-day hostage takers want the virtual currency Bitcoin, <a href="//www.nytimes.com/2015/07/26/business/dealbook/for-ransom-bitcoin-replaces-the-bag-of-bills.html?ref=dealbook">Nathaniel Popper reports in DealBook</a>. <b>Victims of mob shakedowns</b> these days find that their only way out is through a Bitcoin payment. </p>
<p class="story-body-text" itemprop="articleBody"> <b>Criminals like the virtual currency</b> because it can be held in a digital wallet that does not have to be registered with the authorities and can easily be exchanged for real money. At the moment, a single Bitcoin is going for about $290. </p>
<p class="story-body-text" itemprop="articleBody"> Bitcoin makes the <b>delivery of a ransom</b> more seamless and untraceable. Its system is run by a decentralized network of computers that collects no personal information about users. An in-person meeting is unnecessary. Its transactions are also irreversible â victims cannot reclaim their money as they might with a credit card or PayPal transaction. </p>
<p class="story-body-text" itemprop="articleBody"> Although Bitcoin has gained mainstream appeal recently, the proliferation of ransom demands is an unhappy reminder of its continued appeal in <b>the criminal underworld</b>, even after the online black market bazaar Silk Road was shut down. </p>
<p class="story-body-text" itemprop="articleBody"> Some in the Bitcoin community have suggested potential ways to fend off ransom threats, such as <b>digitally marking coins</b> used for ransom payments, but solutions have been held up because of the value that many Bitcoin believers have put in the virtual currencyâs unfettered free movement.</p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>CHINA STOCK SELL-OFF</strong> <span class="divider"> | </span></span> Tumult has returned to Chinaâs stock markets, <a href="//www.nytimes.com/2015/07/28/business/international/chinese-stocks-plummet-in-shanghai-and-shenzhen.html">Neil Gough reports in The New York Times</a>. After several weeks of calm, the main Shanghai share index plunged 8.5 percent on Monday, its   <b>steepest one-day drop in eight years</b>, while Shenzhenâs main index fell 7 percent. </p>
<p class="story-body-text" itemprop="articleBody"> The drop has cast new doubt on the <b>governmentâs measures</b> to support share prices. It has also brought an end to a modest rally that started three weeks ago when the government intervened and engineered a recovery after a slide wiped more than $3 trillion off the market in a matter of weeks. </p>
<p class="story-body-text" itemprop="articleBody"></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong></strong> <span class="divider"> | </span></span> <em>Contact <a href="mailto:amie.tsang@nytimes.com">amie.tsang@nytimes.com</a></em></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<h6 class="kicker"><a href="//dealbook.blogs.nytimes.com/category/mergers-acquisitions/">Mergers &#038; Acquisitions &#187;</a></h6>
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Gambling Firm GVC Sweetens Bid for Rival Bwin.party</strong> <span class="divider"> | </span></span> The online gambling firm GVC Holdings has raised its offer for Bwin.party Digital Entertainment to about 1 billion pounds, topping a recently accepted bid from 888 Holdings Plc.<br /><span class="kicker"><a href="//www.nytimes.com/reuters/2015/07/27/business/27reuters-bwin-party-m-a-gvc-holdings.html">NYT &#187;</a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>BG Says Brazil Approves 47 Billion Pound Shell Takeover</strong> <span class="divider"> | </span></span> The British energy company BG Group, which has agreed to be taken over by Royal Dutch Shell, said it has won approval by the Brazilian competition authorities for the takeover.<br /><span class="kicker"><a href="//www.ft.com/fastft/365871"> THE FINANCIAL TIMES </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Deutsche BÃ¶rse Buys Forex Platform </strong> <span class="divider"> | </span></span> Deutsche BÃ¶rse is buying the foreign exchange trading platform 360T for â¬725 million in a deal that underlines the attraction of the $5.3 trillion-a-day foreign exchange market.<br /><span class="kicker"><a href="//www.ft.com/cms/s/0/25371c70-3370-11e5-bdbb-35e55cbae175.html#axzz3h43hFV1A"> THE FINANCIAL TIMES </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<h6 class="kicker"><a href="//topics.nytimes.com/top/reference/timestopics/subjects/b/banks_and_banking/index.html">INVESTMENT BANKING &#187;</a></h6>
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>UBS Profit Increases 53% in Second Quarter</strong> <span class="divider"> | </span></span> The Swiss bank said its profit of about $1.26 billion was driven by gains in its wealth management business, particularly in the Asia-Pacific region.<br /><span class="kicker"><a href="//www.nytimes.com/2015/07/28/business/dealbook/ubs-earnings-q2.html">NYT &#187;</a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>The Seven-Year Itch</strong> <span class="divider"> | </span></span> It has been nearly seven years since shares of Bank of America or Citigroup traded above book value. It may be that investors donât believe the value of intangible assets on their balance sheets, namely good will that arose from deals mostly struck before the crisis.<br /><span class="kicker"><a href="//www.wsj.com/articles/a-book-bofa-and-citi-cant-pick-up-1437934709?mod=rss_markets_main"> THE WALL STREET JOURNAL </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<h6 class="kicker"><a href="//topics.nytimes.com/top/reference/timestopics/subjects/p/private_equity/index.html">PRIVATE EQUITY &#187;</a></h6>
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Rubenstein Says Private Equityâs Fees Have Changed</strong> <span class="divider"> | </span></span> The private equity industry has changed the most in decades as its investor base evolves and clients demand more fee concessions, according to David Rubenstein, Carlyleâs co-founder and co-chief executive officer.<br /><span class="kicker"><a href="//www.bloomberg.com/news/articles/2015-07-26/rubenstein-says-private-equity-s-fees-investors-have-changed"> BLOOMBERG </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<h6 class="kicker"><a href="//topics.nytimes.com/top/reference/timestopics/subjects/h/hedge_funds/index.html">HEDGE FUNDS &#187;</a></h6>
<div class="ru-story">
<div class="w75 right"><img width="75" height="75" border="0" alt="Puerto Rico Should Collect Unpaid Taxes, Hedge Fund-Backed Economists Say" src="https://static01.nyt.com/images/2015/07/27/business/27RICOjp/27RICOjp-square320.jpg"/></div>
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Puerto Rico Should Collect Unpaid Taxes, Hedge Fund-Backed Economists Say</strong> <span class="divider"> | </span></span> Economists working for firms with investments in Puerto Rican bonds said Sunday night that stepping up tax collections and obtaining additional financing could help solve the territoryâs debt crisis.<br /><span class="kicker"><a href="//www.nytimes.com/2015/07/27/business/dealbook/puerto-rico-should-collect-unpaid-taxes-hedge-fund-economists-say.html">NYT &#187;</a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<h6 class="kicker"><a href="//topics.nytimes.com/top/reference/timestopics/subjects/i/initial_public_offerings/index.html">I.P.O./OFFERINGS &#187;</a></h6>
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>China Railway Signal Begins Taking Orders for $1.8 Billion I.P.O.</strong> <span class="divider"> | </span></span> The state-owned China Railway Signal began taking orders on Monday for its Hong Kong initial public offering, but the rail-signal maker has already sold more than half of available shares to cornerstone investors.<br /><span class="kicker"><a href="//www.wsj.com/articles/china-railway-signal-begins-taking-orders-for-1-8-billion-hong-kong-ipo-1437970432"> THE WALL STREET JOURNAL </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Bioven Seeks I.P.O. to Help Market Cuban Cancer Drug</strong> <span class="divider"> | </span></span> A Malaysian biotech company developing a cancer drug discovered in Cuba is planning to go public in London.<br /><span class="kicker"><a href="//www.ft.com/cms/s/0/a43edd88-326b-11e5-91ac-a5e17d9b4cff.html#axzz3h43hFV1A"> THE FINANCIAL TIMES </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<h6 class="kicker"><a href="//topics.nytimes.com/top/reference/timestopics/subjects/v/venture_capital/index.html">VENTURE CAPITAL &#187;</a></h6>
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Chinaâs GSR Venturesâ $5 Billion Fund</strong> <span class="divider"> | </span></span> The fund is expected to be announced Monday and will target deals to acquire companies in technology, Internet and biotechnology industries globally, The Wall Street Journal reports, citing people familiar with the situation. <br /><span class="kicker"><a href="//www.wsj.com/articles/chinas-gsr-ventures-plans-5-billion-fund-for-overseas-tech-acquisitions-1437909282?mod=asia_home"> THE WALL STREET JOURNAL </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Goldman-Backed Instant Messaging Company Seeks New Investment</strong> <span class="divider"> | </span></span> Symphony, the instant-messaging software company backed by many of Wall Streetâs biggest firms, is seeking another investment round that may value the start-up at as much as $1 billion.<br /><span class="kicker"><a href="//www.wsj.com/articles/goldman-backed-instant-messaging-company-seeks-new-investment-1437934657?mod=rss_markets_main"> THE WALL STREET JOURNAL </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="round-up">
<div class="ru-top-story">
<h6 class="kicker"><a href="//topics.nytimes.com/top/reference/timestopics/subjects/c/credit_crisis/financial_regulatory_reform/index.html">LEGAL/REGULATORY &#187;</a></h6>
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Deregulator of Banks Set to Testify Before House</strong> <span class="divider"> | </span></span> Phil Gramm, one of the chief architects of a sweeping deregulation of the financial industry in the late 1990s, will testify before the House Financial Services Committee on the impact of Dodd-Frank.<br /><span class="kicker"><a href="//www.nytimes.com/2015/07/27/business/dealbook/deregulator-of-banks-set-to-defend-his-actions.html">NYT &#187;</a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>German Regulator Says Ex-Deutsche Bank CEO Did Not Lie on Libor</strong> <span class="divider"> | </span></span> Germany&#8217;s financial watchdog Bafin has cleared Deutsche Bank&#8217;s former co-chief executive Anshu Jain of lying to the Bundesbank during investigations into interest rate manipulation, the Financial Times reported on Saturday.<br /><span class="kicker"><a href="//www.nytimes.com/reuters/2015/07/25/business/25reuters-deutschebank-libor-bafin.html">NYT &#187;</a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>China Seeks to Tame Online Finance Risks</strong> <span class="divider"> | </span></span> Chinaâs move to regulate Internet finance is a positive step toward legitimizing a sector that has largely operated in a vacuum, analysts say, but the rules also reflect the governmentâs support for incumbent banks.<br /><span class="kicker"><a href="//www.ft.com/cms/s/0/aea850ee-311f-11e5-8873-775ba7c2ea3d.html#ixzz3h5227lq9"> THE FINANCIAL TIMES</a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story -->
<div class="ru-story">
<p class="story-body-text" itemprop="articleBody"><span class="title"><strong>Bloomberg Becomes Regulated Trading Venue in Europe</strong> <span class="divider"> | </span></span> Bloomberg was formally granted a license to run a âmultilateral trading facilityâ in Britain by the Financial Services Authority. <br /><span class="kicker"><a href="//www.ft.com/cms/s/0/23998700-321b-11e5-91ac-a5e17d9b4cff.html#ixzz3h4yudBmH"> THE FINANCIAL TIMES </a></span></p>
</div>
<p class="story-body-text" itemprop="articleBody"><!-- end .ru-story --></div>
</div>
<div class="newsletter-signup">
<p class="story-body-text" itemprop="articleBody"><a href="//dealbook.nytimes.com/dealbook-e-mail/">Sign up for the DealBook Newsletter</a>, delivered every morning and afternoon.</p>
</div>
<p class="story-body-text" itemprop="articleBody"></p>
</div>
			<footer class="entry-footer">
				
				<div id="sharetools-post-footer" class="sharetools theme-classic"
					data-shares="show-all|Share"
					data-url="//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/"
					data-title="Morning Agenda: Teva to Buy Allergan Generic Drug Unit"
					data-description="&lt;span class=&quot;excerpt-inner&quot;&gt;Fidelity Seen as Muscling In | Pearson Discusses Selling Economist Stake | Bitcoin is the New Ransom Currency | China Stock Sell-Off&lt;/span&gt;&lt;a href=&quot;//news.blogs.nytimes.com/2015/07/27/morning-agenda-teva-to-buy-allergan-generic-drug-unit/&quot; class=&quot;more-link&quot;&gt;Read&nbsp;more...&lt;/a&gt;"
					>
					<div class="ad sharetools-inline-article-ad hidden"></div>
				</div>
				<div class="footer-tags">
									</div>
			</footer>
		</article>
		<section id="whats-next" class="whats-next nocontent robots-nocontent">
    <h2 class="visually-hidden">What's Next</h2>
    <div class="nocontent robots-nocontent">
        <div class="loader-container">
            <div class="loader loader-t-logo-32x32-ecedeb-ffffff"><span class="visually-hidden">Loading...</span></div>
        </div>
    </div><!-- close nocontent -->
</section>

		</div> <!-- end content -->
</div><!-- end .a-column -->
<div class="cColumn nocontent robots-nocontent">
	<aside>
			<div class="module ad" id="MiddleRight"></div>
        	</aside>
</div>		<div class="clear"></div>
	</div><!-- end blog wrap -->
	<div class="hideContent"></div>

	
<!-- Google Analytics start -->
<script type="text/javascript">
(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;if (!/NYT-T=out/.test(document.cookie)) {m.parentNode.insertBefore(a,m)} })(window,document,'script','//www.google-analytics.com/analytics.js','ga');
ga('create', 'UA-4406282-154',  { 'alwaysSendReferrer': true } );
ga('send', 'pageview');
</script>
<!-- Google Analytics end -->
		<div id="mobilebanner2" class="ad mobilebanner2"></div>
		<div class="accessibility-ad-header visually-hidden">
    <p>Advertisement</p>
</div>
<div id="SponLink" class="text-ad bottom-left-ad nocontent robots-nocontent"></div>

		<div id="Top5" class="ad top5-ad hidden nocontent robots-nocontent"></div>

					</div>
			<div class="search-overlay"></div>
		</main><!-- close main -->
						<footer id="page-footer" class="page-footer" role="contentinfo">
    <nav>
         <ul>
             <li>
                <a href="https://www.nytco.com" itemprop="copyrightNotice">
                    &copy; <span itemprop="copyrightYear">2017</span>
					<span itemprop="copyrightHolder provider sourceOrganization" itemscope
						itemtype="//schema.org/Organization"
						itemid="//www.nytimes.com">
						<span itemprop="name"> The New York Times Company</span>
						<meta itemprop="tickerSymbol" content="NYSE NYT"/>
					</span>
                </a>
            </li>
            <li><a href="https://www.nytimes.com/ref/membercenter/help/infoservdirectory.html">Contact Us</a></li>
            <li><a href="//www.nytco.com/careers/">Work With Us</a></li>
            <li><a href="//nytmediakit.com/">Advertise</a></li>
            <li><a href="https://www.nytimes.com/content/help/rights/privacy/policy/privacy-policy.html#pp">Your Ad Choices</a></li>
            <li><a href="https://www.nytimes.com/privacy">Privacy</a></li>
            <li><a href="https://www.nytimes.com/ref/membercenter/help/agree.html" itemprop="usageTerms">Terms of Service</a></li>
            <li class="last-item"><a href="https://www.nytimes.com/content/help/rights/sale/terms-of-sale.html">Terms of Sale</a></li>
         </ul>
    </nav>
    <nav class="last-nav">
        <ul>
            <li><a href="//spiderbites.nytimes.com">Site Map</a></li>
            <li><a href="https://www.nytimes.com/membercenter/sitehelp.html">Help</a></li>
            <li><a href="https://myaccount.nytimes.com/membercenter/feedback.html">Site Feedback</a></li>
            <li class="last-item"><a href="https://www.nytimes.com/subscriptions/Multiproduct/lp5558.html?campaignId=37WXW">Subscriptions</a></li>
        </ul>
    </nav>
</footer>		</div><!-- close shell -->
	<script>
require(['foundation/main'], function () {
    require(['blogs/main']);
    require(['jquery/nyt', 'foundation/views/page-manager'], function ($, pageManager) {
        if (window.location.search.indexOf('disable_tagx') > 0) {
            return;
        }
        $(document).ready(function () {
            require(['https://a1.nyt.com/analytics/json-kidd.min.js'], function () {
                pageManager.trackingFireEventQueue();
            });
        });
    });
});
</script>

	<div id="Inv1" class="ad inv1-ad hidden"></div>
<div id="Inv2" class="ad inv2-ad hidden"></div>
<div id="Inv3" class="ad inv3-ad hidden"></div>
<div id="ab1" class="ad ab1-ad hidden"></div>
<div id="ab2" class="ad ab2-ad hidden"></div>
<div id="ab3" class="ad ab3-ad hidden"></div>
<div id="prop1" class="ad prop1-ad hidden"></div>
<div id="prop2" class="ad prop2-ad hidden"></div>
<div id="Anchor" class="ad anchor-ad hidden"></div>
<div id="ADX_CLIENTSIDE" class="ad adx-clientside-ad hidden"></div>
		<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","licenseKey":"b5bcf2eba4","applicationID":"5164608","transactionName":"YwFXZhRYVhAEVUZcX1pLYEAPFlkTFRtQWV9TFxtCDkk=","queueTime":0,"applicationTime":48,"ttGuid":"","agentToken":"","userAttributes":"","errorBeacon":"bam.nr-data.net","agent":""}</script></body>
</html>
